2-(2,3-dicarboxycyclopropyl)glycine has been researched along with Disease Models, Animal in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Machado, A; Mauriño, R; Santiago, M; Venero, JL | 1 |
| Aas, P; Enger, S; Myhrer, T | 1 |
| Clinckers, R; Ebinger, G; Lindekens, H; Lodge, D; Meurs, A; Michotte, Y; O'Neill, MJ; Smolders, I | 1 |
| Cano, J; Machado, A; Rite, I; Venero, JL | 1 |
| Brose, N; Gibson, HE; Jones, S; Morton, AJ; Reim, K | 1 |
| Bai, HM; Fei, Z; Jiang, XF; Wang, XL; Zhang, X | 1 |
| Cano, J; Machado, A; Matarredona, ER; Santiago, M; Venero, JL | 1 |
7 other study(ies) available for 2-(2,3-dicarboxycyclopropyl)glycine and Disease Models, Animal
| Article | Year |
|---|---|
Striatal ablation of GABAergic neurons prevents the in vivo neuroprotective effect of DCG-IV against the MPP+-induced neurotoxicity on dopaminergic nerve terminals.
Topics: Animals; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Glycine; Male; Neuroprotective Agents; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Wistar | 2010 |
The perirhinal cortex of rats: an intricate area for microinfusion of anticonvulsants against soman-induced seizures.
Topics: Animals; Anticonvulsants; Brain Waves; Catheters, Indwelling; Cerebral Cortex; Cyclopentanes; Cyclopropanes; Disease Models, Animal; Drug Delivery Systems; Electroencephalography; Glycine; Infusions, Parenteral; Male; Micromanipulation; Procyclidine; Pyridines; Rats; Rats, Wistar; Reaction Time; Seizures; Soman; Time Factors | 2013 |
In vivo modulation of extracellular hippocampal glutamate and GABA levels and limbic seizures by group I and II metabotropic glutamate receptor ligands.
Topics: Amino Acids; Animals; Anticonvulsants; Benzoates; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Disease Models, Animal; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Extracellular Fluid; gamma-Aminobutyric Acid; Glutamic Acid; Glycine; Hippocampus; Ligands; Limbic System; Male; Microdialysis; Pilocarpine; Pyridines; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Seizures | 2004 |
Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Corpus Striatum; Cyclopropanes; Denervation; Disease Models, Animal; Down-Regulation; Female; Glutamate Decarboxylase; Glycine; Huntington Disease; N-Methylaspartate; Neural Pathways; Neurons; Neurotoxins; Proto-Oncogene Proteins c-fos; Quinolinic Acid; Rats; Rats, Wistar; Receptor, trkB; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus; Tyrosine 3-Monooxygenase | 2005 |
A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse.
Topics: 2-Amino-5-phosphonovalerate; Adaptor Proteins, Vesicular Transport; Age Factors; Animals; Anticonvulsants; Colforsin; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Electric Stimulation; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Glycine; Hippocampus; Huntington Disease; In Vitro Techniques; Long-Term Potentiation; Mice; Mice, Knockout; Mossy Fibers, Hippocampal; Nerve Tissue Proteins; Patch-Clamp Techniques; Time Factors | 2005 |
Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury.
Topics: Animals; Body Water; Brain; Brain Edema; Cell Death; Cyclopropanes; Diffuse Axonal Injury; Disease Models, Animal; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glycine; Injections, Intraventricular; Male; Nerve Degeneration; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Treatment Outcome | 2006 |
Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoates; Brain-Derived Neurotrophic Factor; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine; Dopamine Agents; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glycine; Immunohistochemistry; In Situ Hybridization; Male; Microdialysis; Microglia; MPTP Poisoning; Neurons; Presynaptic Terminals; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; RNA, Messenger | 2001 |